Myelodysplastic Syndrome
Advertisement
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, discusses her experiences and shares resources.
National Cancer Survivors Month is marked in June each year.
Valeria Santini, MD, shares her insights during the European Hematology Association 2024 Congress.
Researchers developed and piloted a novel phone-delivered positive psychology intervention called PATH.
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Survival rates for myelodysplastic syndromes (MDS) varies widely – from months to decades – highlighting the need for ...
For post-transplant disease control in patients with myelodysplastic syndromes (MDS), donor lymphocyte infusion (DLI) has ...
Compared with placebo, treatment with CC-486, the oral formulation of the hypomethylating agent (HMA) azacitidine ...
Results from a randomized, proof-of-concept, phase II study demonstrated promising overall survival (OS), event-free survival ...
In a prospective multicenter study, older patients with myelodysplastic syndromes (MDS) who underwent reduced-intensity ...
Treatment with enasidenib, a small molecule inhibitor of mutant IDH2, showed promising clinical activity in patients with ...
A study published in Hematology, Transfusion & Cell Therapy found that FLT3, NPM1, IDH1, and IDH2 gene mutations may ...
A study published in Cancer Causes & Control observed that smoking, history of autoimmune disease, and benzene exposure ...
The use of poly (ADP-ribose) polymerase (PARP) inhibitors increased the risk of developing myelodysplastic syndromes (MDS) ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.